Will a vaccine targeting the Omicron variant be available in the US before April 1, 2022?
$29,057 Vol.
Rules
If a vaccine engineered to specifically provide protection against the Omicron variant of COVID-19, whether or not it additionally protects against other variants of SARS-CoV-2, is released for public use in the US, regardless of whether its use is restricted to particular population segments, before April 1, 2022, 12:00:00 AM ET, this market will resolve to “Yes.” Otherwise this market will resolve to “No”.
The source used to resolve this market will be official information released by the FDA (https://www.fda.gov/emergency-preparedness-and-response/mcm-legal-regulatory-and-policy-framework/emergency-use-authorization) and/or other official information from the government of the United States of America.
Note, this market is only for a vaccine’s availability in the United States, and does not cover any vaccine’s availability in any other country.
The source used to resolve this market will be official information released by the FDA (https://www.fda.gov/emergency-preparedness-and-response/mcm-legal-regulatory-and-policy-framework/emergency-use-authorization) and/or other official information from the government of the United States of America.
Note, this market is only for a vaccine’s availability in the United States, and does not cover any vaccine’s availability in any other country.
Created At: Jan 25, 2022, 12:00 AM UTC
Volume
$29,057End Date
Apr 1, 2022Created At
Jan 25, 2022, 12:00 AM UTCOutcome proposed: No
No dispute
Final outcome: No
$29,057 Vol.
Will a vaccine targeting the Omicron variant be available in the US before April 1, 2022?
About
If a vaccine engineered to specifically provide protection against the Omicron variant of COVID-19, whether or not it additionally protects against other variants of SARS-CoV-2, is released for public use in the US, regardless of whether its use is restricted to particular population segments, before April 1, 2022, 12:00:00 AM ET, this market will resolve to “Yes.” Otherwise this market will resolve to “No”.
The source used to resolve this market will be official information released by the FDA (https://www.fda.gov/emergency-preparedness-and-response/mcm-legal-regulatory-and-policy-framework/emergency-use-authorization) and/or other official information from the government of the United States of America.
Note, this market is only for a vaccine’s availability in the United States, and does not cover any vaccine’s availability in any other country.
The source used to resolve this market will be official information released by the FDA (https://www.fda.gov/emergency-preparedness-and-response/mcm-legal-regulatory-and-policy-framework/emergency-use-authorization) and/or other official information from the government of the United States of America.
Note, this market is only for a vaccine’s availability in the United States, and does not cover any vaccine’s availability in any other country.
Volume
$29,057End Date
Apr 1, 2022Created At
Jan 25, 2022, 12:00 AM UTCOutcome proposed: No
No dispute
Final outcome: No
Beware of external links.
Beware of external links.




Beware of external links.
Beware of external links.